Corvus Pharmaceuticals Stock Price

0.10 (3.08%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 209,751
Bid Price 3.33
Ask Price 3.49
News -
Day High 3.359


52 Week Range


Day Low 3.19
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Corvus Pharmaceuticals Inc CRVS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 3.08% 3.35 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.23 3.19 3.359 3.34 3.25
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,769 209,751 $ 3.29 $ 690,986 - 1.86 - 9.54
Last Trade Time Type Quantity Stock Price Currency
18:37:53 formt 152 $ 3.35 USD


Draw Mode:

Corvus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 155.94M 46.55M 33.63M $ - $ - -0.20 44.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -1.47M 0.60%

more financials information »

Corvus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRVS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.553.642.993.20641,779-0.20-5.63%
1 Month4.804.872.993.61786,297-1.45-30.21%
3 Months2.269.542.226.098,960,6891.0948.23%
6 Months2.769.541.865.984,255,6760.5921.38%
1 Year4.109.541.865.662,483,924-0.75-18.29%
3 Years5.869.541.015.361,148,354-2.51-42.83%
5 Years16.36122.13661.015.65730,050-13.01-79.52%

Corvus Pharmaceuticals Description

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Your Recent History
Corvus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.